Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Trial of Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Next Previous
Trial Profile

Phase I/II Trial of Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Avelumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Large cell carcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium
    • 16 Jan 2019 Status changed from suspended to recruiting.
    • 05 Oct 2018 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top